title: Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib.
abstract: A papulopustular rash occurs in 45-100% of patients undergoing anti-cancer treatment with epidermal growth factor (EGFR) inhibitors. Although the majority of cases involve the face and upper trunk, ultraviolet radiation has not yet been documented to play a major role in inducing or exacerbating symptoms. We describe a 75-year-old man who was being treated with the EGFR inhibitor erlotinib and developed the characteristic rash on unprotected areas of the trunk after photoexposure, while the protected areas (face and neck) remained uninvolved. This case underscores the importance of sun protection in patients treated with EGFR inhibitors and supports in vitro data showing that EGFR blockade results in altered keratinocyte survival and proliferation in response to ultraviolet radiation.
authors.affiliation: Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.
authors.forename: Minnelly
authors.initials: M
authors.lastname: Luu
authors.forename: Susan E
authors.initials: SE
authors.lastname: Lai
authors.forename: Jyoti
authors.initials: J
authors.lastname: Patel
authors.forename: Joan
authors.initials: J
authors.lastname: Guitart
authors.forename: Mario E
authors.initials: ME
authors.lastname: Lacouture
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D017484:Dermatitis, Phototoxic / Q000209:etiology*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride